Kidney StoneNCT01812772
The Effect of Ureteric Stent Tethers on Patient Symptoms and Urinary Infection
A study testing Double J-stent with a long tether and Double J-stent without a long tether in people with Kidney Stone, run by Unity Health Toronto at 1 site in Canada.
Trial summary
RESEARCH QUESTION Do ureteric stents with tethers, left in-situ for 1-2 weeks, increase the rate of stent bacterial colonization, urinary bacterial colonization and stent related lower urinary tract symptoms compared to stents without tethers? HYPOTHESIS We hypothesize that ureteral double-J stents with tethers… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Kidney Stone
- What is being tested?
- Double J-stent with a long tether and Double J-stent without a long tether
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 11 participants
- Where
- 1 siteCanada
- Study dates
- Mar 2013to Feb 2014
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age over 18 years
- First presentation for ureteroscopy for this particular stone
- Planned insertion of a double J-stent
- Follow-up conducted at St. Michael's Hospital
Who cannot join
- Age <18years
- Preexisting stent in place
- Bilateral ureteric stents to be inserted
- Patients with congenital kidney anomalies (horseshoe kidney, ectopic kidney, etc.)
- Patients with an indwelling foley catheter
- Patients with neurogenic bladder, chronic prostatitis, painful bladder syndrome or interstitial cystitis
Show all 11Show fewer
- Patients with a urinary diversion (ileal conduit, ileal neobladder)
- Patient currently taking an α-blocker (alfuzosin, terazosin,tamsulosin, prazosin)
- Active urinary tract infection or positive screening urine culture at preadmission
- Pregnancy
- Patients who will not be returning to St. Michael's Hospital for follow-up
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Effect of Ureteric Stent Tethers on Patient Symptoms, Stent Bacterial Colonization and Urinary Tract Infection
RESEARCH QUESTION Do ureteric stents with tethers, left in-situ for 1-2 weeks, increase the rate of stent bacterial colonization, urinary bacterial colonization and stent related lower urinary tract symptoms compared to stents without tethers?
HYPOTHESIS We hypothesize that ureteral double-J stents with tethers increase the rate of stent bacterial colonization, but do not increase the rate of urinary bacterial colonization or stent related lower urinary tract symptoms compared to stents without tethers when left in-situ for 1-2 weeks.
Read the detailed description
Two of the main issues surrounding the use of ureteral stents are stent related symptoms and bacterial colonization/urinary tract infection (UTI). To be useful, stent tethers must decrease the morbidity associated with stent removal and the cost to the health care system, while not increasing stent related symptoms or UTI. To our knowledge, the effect of leaving a stent tether on stent symptoms and bacterial colonization of the stent and urine has not been previously studied.
This is a single-centre, prospective, randomized, controlled trial. Patients eligible for recruitment into the study based on the inclusion and exclusion criteria will be provided with a consent form at the time of their initial appointment, when their ureteroscopy is being booked. Once consent is obtained, patients will be randomized (using random number table look-up) to receive either double-J stent placement with a tether (the Treatment Group) or double-J stent placement without a tether (the Control Group) following ureteroscopy. Randomization will occur prior to the commencement of ureteroscopy.
Patients will either have a double J-stent placed with or without a long tether attached. The double-J stents used in the treatment and control groups will be otherwise identical. All stents will be 6 French in diameter and 22-26 cm in length based on the patients' height. Sizing of stent length will be performed uniformly in the treatment and control group and will involve measuring ureteric length from the ureteropelvic junction to ureterovesical junction with a marked ureteral catheter. All patients will receive a single preoperative dose of prophylactic antibiotics (i.e., Ampicillin and Gentamicin or Ciprofloxacin).All patients will have a urine sample collected for culture and sensitivity at the start of the procedure.
Blinding will not be feasible during this trial due to the nature of the intervention. The urologist performing the procedure will clearly be aware of whether a tether is left on the stent. Similarly, patients will also be aware of whether a string tether is protruding from their urethral meatus or not. However, assessors of the compiled data and questionnaires will be blinded to the intervention.
Once enrolled in the study, patients will be given the Ureteral Stent Symptoms Questionnaire 1 (Pre Stent) to complete prior to undergoing ureteroscopy and stent insertion. This will allow us to establish baseline lower urinary tract symptoms.
After completion of ureteroscopy and stent insertion and upon discharge from the hospital all patients will be provided with the following:
- Diary sheets to record daily analgesic use
- A prescription for a standardized analgesic regimen including Percocet (1 tablet PO q6h prn, 20 tablets) to be taken as needed for pain control.
- An appointment for the first follow-up visit (in 7-14 days)
At the follow-up visit, a kidney, ureter and bladder (KUB) radiograph will be performed and patients will complete the Ureteral Stent Symptoms Questionnaire 2 (Stent insitu). The KUB x-ray will be reviewed to ensure the stent remained in appropriate position and did not migrate and that any residual stone fragments have passed. Next, all patients will have their stent removed. Patients in the control group will undergo cystoscopy under local anesthesia for stent removal and those the treatment group will have the stent removed by the tether. This distal curl or lower end (bladder) of the double-J stent, in all patients, will be sent to microbiology for culture to determine the rate of stent bacterial colonization. Of note, all patients in the control group will provide a mid-stream urine sample to be sent for culture and sensitivity testing, after cystoscopy and stent removal, while all patients in the treatment group will provide a urine sample after the stent is removed, so the tether does not contaminate the sample. This urine sample will allow us to establish the rate of bacteriuria.
Upon discharge from the Cystoscopy unit following stent removal all patients will return for a final follow-up with renal ultrasound approximately 4-6 weeks post-stent removal and will be given the Ureteral Stent Symptoms Questionnaire 3 (Post Stent) to complete.
- Conditions
- Kidney Stone
- Being tested
- Double J-stent with a long tether, Double J-stent without a long tether
- Keywords
- urinary stents, ureteroscopy
- Medical subject headings
- Kidney Calculi
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Double J-stent with a long tetherDevice
Patients will receive a double-J stent placement with a long tether following ureteroscopy.
Double J-stent without a long tetherDevice
Patients will receive a double-J stent placement without a long tether following ureteroscopy.
| Study group | Role | What they receive |
|---|---|---|
| Double J-stent with a long tether | Experimental | Following ureteroscopy patients will have placed a double J-stent with a long tether. Receives: Device: Double J-stent with a long tether |
| Double J-stent without a long tether | Active comparator | Following ureteroscopy patients will have a double J-stent placed without a long tether Receives: Device: Double J-stent without a long tether |
What is being measured
The primary outcome is the main question the study is designed to answer.
The difference in stent related lower urinary tract symptoms based on mean scores from the Ureteral Stent Symptoms questionnaires
Measured: The Ureteral Stent Symptoms Questionnaires will be completed before the procedure, 1 week after the procedure and 1 month after the stent was removed (5 weeks post procedure)
Secondary outcomes (1)
the rate of stent bacterial colonization
Measured: 1 week post procedure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Mar 2013 (estimated)
- Study startMar 2013
- Primary completionFeb 2014
- Study completionFeb 2014
Why it stopped: Low enrollment
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Kidney StoneStudies of the same condition, open and under way.
- More trials run by Unity Health TorontoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 11 participants (actual)
Sponsor and investigators
- Lead sponsor
- Unity Health Toronto
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- R. John D Honey, MD FRCSC, Principal investigator, Unity Health TorontoKenneth T Pace, MD FRCSC, Principal investigator, Unity Health Toronto
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01812772
- Sponsor's protocol ID
- 10-370
- Status last verified
- Feb 2014
- First submitted
- 14 Mar 2013
- Last updated
- 21 May 2015
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 May 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Ureteric Stent Tethers on Patient Symptoms, Stent Bacterial Colonization and Urinary Tract Infection
- ClinicalTrials.gov ID
- NCT01812772
- Acronym / sponsor ID
- 10-370
- Conditions
- Kidney Stone
- Keywords
- urinary stents, ureteroscopy
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Low enrollment
- Enrolment
- 11 participants (actual)
- Lead sponsor
- Unity Health TorontoUniversity, hospital or other
- Study start
- Mar 2013
- Primary completion
- Feb 2014 (actual)
- Study completion
- Feb 2014 (actual)
- First posted
- 18 Mar 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RESEARCH QUESTION Do ureteric stents with tethers, left in-situ for 1-2 weeks, increase the rate of stent bacterial colonization, urinary bacterial colonization and stent related lower urinary tract symptoms compared to stents without tethers?
HYPOTHESIS We hypothesize that ureteral double-J stents with tethers increase the rate of stent bacterial colonization, but do not increase the rate of urinary bacterial colonization or stent related lower urinary tract symptoms compared to stents without tethers when left in-situ for 1-2 weeks.
Detailed description
Two of the main issues surrounding the use of ureteral stents are stent related symptoms and bacterial colonization/urinary tract infection (UTI). To be useful, stent tethers must decrease the morbidity associated with stent removal and the cost to the health care system, while not increasing stent related symptoms or UTI. To our knowledge, the effect of leaving a stent tether on stent symptoms and bacterial colonization of the stent and urine has not been previously studied.
This is a single-centre, prospective, randomized, controlled trial. Patients eligible for recruitment into the study based on the inclusion and exclusion criteria will be provided with a consent form at the time of their initial appointment, when their ureteroscopy is being booked. Once consent is obtained, patients will be randomized (using random number table look-up) to receive either double-J stent placement with a tether (the Treatment Group) or double-J stent placement without a tether (the Control Group) following ureteroscopy. Randomization will occur prior to the commencement of ureteroscopy.
Patients will either have a double J-stent placed with or without a long tether attached. The double-J stents used in the treatment and control groups will be otherwise identical. All stents will be 6 French in diameter and 22-26 cm in length based on the patients' height. Sizing of stent length will be performed uniformly in the treatment and control group and will involve measuring ureteric length from the ureteropelvic junction to ureterovesical junction with a marked ureteral catheter. All patients will receive a single preoperative dose of prophylactic antibiotics (i.e., Ampicillin and Gentamicin or Ciprofloxacin).All patients will have a urine sample collected for culture and sensitivity at the start of the procedure.
Blinding will not be feasible during this trial due to the nature of the intervention. The urologist performing the procedure will clearly be aware of whether a tether is left on the stent. Similarly, patients will also be aware of whether a string tether is protruding from their urethral meatus or not. However, assessors of the compiled data and questionnaires will be blinded to the intervention.
Once enrolled in the study, patients will be given the Ureteral Stent Symptoms Questionnaire 1 (Pre Stent) to complete prior to undergoing ureteroscopy and stent insertion. This will allow us to establish baseline lower urinary tract symptoms.
After completion of ureteroscopy and stent insertion and upon discharge from the hospital all patients will be provided with the following:
- Diary sheets to record daily analgesic use
- A prescription for a standardized analgesic regimen including Percocet (1 tablet PO q6h prn, 20 tablets) to be taken as needed for pain control.
- An appointment for the first follow-up visit (in 7-14 days)
At the follow-up visit, a kidney, ureter and bladder (KUB) radiograph will be performed and patients will complete the Ureteral Stent Symptoms Questionnaire 2 (Stent insitu). The KUB x-ray will be reviewed to ensure the stent remained in appropriate position and did not migrate and that any residual stone fragments have passed. Next, all patients will have their stent removed. Patients in the control group will undergo cystoscopy under local anesthesia for stent removal and those the treatment group will have the stent removed by the tether. This distal curl or lower end (bladder) of the double-J stent, in all patients, will be sent to microbiology for culture to determine the rate of stent bacterial colonization. Of note, all patients in the control group will provide a mid-stream urine sample to be sent for culture and sensitivity testing, after cystoscopy and stent removal, while all patients in the treatment group will provide a urine sample after the stent is removed, so the tether does not contaminate the sample. This urine sample will allow us to establish the rate of bacteriuria.
Upon discharge from the Cystoscopy unit following stent removal all patients will return for a final follow-up with renal ultrasound approximately 4-6 weeks post-stent removal and will be given the Ureteral Stent Symptoms Questionnaire 3 (Post Stent) to complete.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Double J-stent with a long tether | Experimental | Device: Double J-stent with a long tetherFollowing ureteroscopy patients will have placed a double J-stent with a long tether. |
| Double J-stent without a long tether | Active comparator | Device: Double J-stent without a long tetherFollowing ureteroscopy patients will have a double J-stent placed without a long tether |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Age over 18 years
- First presentation for ureteroscopy for this particular stone
- Planned insertion of a double J-stent
- Follow-up conducted at St. Michael's Hospital
Key exclusion criteria (11 listed)
- Age <18years
- Preexisting stent in place
- Bilateral ureteric stents to be inserted
- Patients with congenital kidney anomalies (horseshoe kidney, ectopic kidney, etc.)
- Patients with an indwelling foley catheter
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Double J-stent with a long tetherPatients will receive a double-J stent placement with a long tether following ureteroscopy. | Device | Double J-stent with a long tether |
| Double J-stent without a long tetherPatients will receive a double-J stent placement without a long tether following ureteroscopy. | Device | Double J-stent without a long tether |
Primary outcome
The difference in stent related lower urinary tract symptoms based on mean scores from the Ureteral Stent Symptoms questionnaires
Time frame: The Ureteral Stent Symptoms Questionnaires will be completed before the procedure, 1 week after the procedure and 1 month after the stent was removed (5 weeks post procedure)
1 secondary outcome
the rate of stent bacterial colonization
Time frame: 1 week post procedure
Results and safety
The study was stopped early (reason given: Low enrollment). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 May 2015.
Related trials for Kidney Stone
Not yet recruiting
Automated Versus Manual Irrigation During Flexible Ureteroscopy
Renal Stone Disease
Not yet recruiting
Optimal Intrarenal Pressure During Flexible Ureteroscopy
Renal Stone Disease
RecruitingObservational study
Stone Clearance With Aspiration vs Other Technologies: a Real-world Evidence Study
Urolithiasis, Stones, Kidney
Not yet recruiting
Intertransverse Process Block Versus Erector Spinae Plane Block for Postoperative Analgesia After Percutaneous Nephrolithotomy
Kidney Stones, Urolithiasis, Hypocitraturia, Pain, Postoperative
Not yet recruiting
Comparison of Smart Pressure-Controlled Flexible Ureteroscopy and Flexible Suction Ureteral Access Sheath-Assisted Flexible Ureteroscopy for 2-3 cm Renal Stones
Kidney Stones
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
R. John D Honey, MD FRCSC principal investigator
Unity Health Toronto
Kenneth T Pace, MD FRCSC principal investigator
Unity Health Toronto
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Double J-stent with a long tether and Double J-stent without a long tether in people with Kidney Stone, run by Unity Health Toronto at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 21 May 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Low enrollment). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The difference in stent related lower urinary tract symptoms based on mean scores from the Ureteral Stent Symptoms questionnaires (time frame: The Ureteral Stent Symptoms Questionnaires will be completed before the procedure, 1 week after the procedure and 1 month after the stent was removed (5 weeks post procedure)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 May 2015.